VVUS Description — Vivus Inc
VIVUS is a pharmaceutical company with approved therapies and one product candidate in clinical development. Qsymia® (phentermine and topiramate extended release) is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management. PANCREAZE®/ PANCREASE® MT (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. STENDRA® (avanafil) is approved by FDA for erectile dysfunction (ED) and by the European Commission under the trade name SPEDRA, for the treatment of ED in the European Union.VI-0106 (tacrolimus) is in clinical development and is being studied in patients with pulmonary arterial hypertension.
|
Free VVUS Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|